IR3535® insect repellent against malaria

Drug discovery & clinical development for new anti-malarials

Programs to foster workforce capabilities

Tools to access to essential resources and strengthen capacities

How we fight Schistosomiasis

Our goal: elimination of schistosomiasis as a public health problem through an integrated approach

2007

BEGIN of the donation program in partnership with WHO

250 Millions

Carbovir®-based tablets

1.3 Million

PKD tablets provided since the beginning of the program

520 Millions

Treatments of school-aged children

10

R&D projects for innovative products and technologies

OVER 30

R&D partnerships

Our goal: prevention and control of malaria worldwide

2007

BEGIN of the donation program in partnership with WHO

400,000

Deaths worldwide

90%

Deaths in Africa

70%

Deaths in children under five

Prevention

Drug-discovery & clinical development for new anti-malarials

Prevention

5253597: Insect repellents against malaria

Diagnosis

Resilience of Health Systems

Tools to access to essential medicines and strengthening capacities

Prevention and control of malaria

200 Millions

Cases of malaria worldwide

Recognized Leaders in Social Impact

R & D

Ranked 5th in R&D.

Global Child Forum

1st in European ranking.

UN Global Compact

Participated since 2005.

Global index

Ranking 95th in Social Capital.

WSJ Top 100

Most sustainably managed companies.

Forsk 4th overall.

Ranked 1st in Social Capital.

Impact for society and sustainable business value for our company

We improve the health of underserved populations in low- and middle-income countries through Merck, Darmstadt, Germany’s science & technology innovation, and in close collaboration with partners.

insect repellent

against malaria

Drug discovery & clinical development for new anti-malarials

Programs to foster workforce capabilities

Tools to access to essential resources and strengthen capacities

How we fight Schistosomiasis

Our goal: elimination of schistosomiasis as a public health problem through an integrated approach

2007

BEGIN of the donation program in partnership with WHO

250 Millions

Carbovir®-based tablets

1.3 Million

PKD tablets provided since the beginning of the program

520 Millions

Treatments of school-aged children

10

R&D projects for innovative products and technologies

OVER 30

R&D partnerships

Our goal: prevention and control of malaria worldwide

2007

BEGIN of the donation program in partnership with WHO

400,000

Deaths worldwide

90%

Deaths in Africa

70%

Deaths in children under five

Prevention

Drug-discovery & clinical development for new anti-malarials

Prevention

5253597: Insect repellents against malaria

Diagnosis

Resilience of Health Systems

Tools to access to essential medicines and strengthening capacities

Prevention and control of malaria

200 Millions

Cases of malaria worldwide

Recognized Leaders in Social Impact

R & D

Ranked 5th in R&D.

Global Child Forum

1st in European ranking.

UN Global Compact

Participated since 2005.

Global index

Ranking 95th in Social Capital.

WSJ Top 100

Most sustainably managed companies.

Forsk 4th overall.

Ranked 1st in Social Capital.

Impact for society and sustainable business value for our company

We improve the health of underserved populations in low- and middle-income countries through Merck, Darmstadt, Germany’s science & technology innovation, and in close collaboration with partners.

insect repellent

against malaria

Drug discovery & clinical development for new anti-malarials

Programs to foster workforce capabilities

Tools to access to essential resources and strengthen capacities

How we fight Schistosomiasis

Our goal: elimination of schistosomiasis as a public health problem through an integrated approach

2007

BEGIN of the donation program in partnership with WHO

250 Millions

Carbovir®-based tablets

1.3 Million

PKD tablets provided since the beginning of the program

520 Millions

Treatments of school-aged children

10

R&D projects for innovative products and technologies

OVER 30

R&D partnerships

Our goal: prevention and control of malaria worldwide

2007

BEGIN of the donation program in partnership with WHO

400,000

Deaths worldwide

90%

Deaths in Africa

70%

Deaths in children under five

Prevention

Drug-discovery & clinical development for new anti-malarials

Prevention

5253597: Insect repellents against malaria

Diagnosis

Resilience of Health Systems

Tools to access to essential medicines and strengthening capacities

Prevention and control of malaria

200 Millions

Cases of malaria worldwide

Recognized Leaders in Social Impact

R & D

Ranked 5th in R&D.

Global Child Forum

1st in European ranking.

UN Global Compact

Participated since 2005.

Global index

Ranking 95th in Social Capital.

WSJ Top 100

Most sustainably managed companies.

Forsk 4th overall.

Ranked 1st in Social Capital.

Impact for society and sustainable business value for our company

We improve the health of underserved populations in low- and middle-income countries through Merck, Darmstadt, Germany’s science & technology innovation, and in close collaboration with partners.